Moreover, they found that patients injected with anti-PD-1 exhibited downregulation of HLA-I expression, while the expression of CTL and GZMB was not significantly different from that of normal individuals, potentially contributing to tumor immune tolerance. The gene discussed is PDCD1; the disease is neoplasm.